The burden trend and risk factors of multiple myeloma from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021

Chang Wang, Yan Guo, Ning Wang, Qianqian Ren, Xu Yuan, Songlin Lu, Yuping Zou, Ruilin Li, Jiacheng Wang, Linna Yuan, Wei She, Hongsheng Tian, Shuo Bi, Xuying Guo, Mao Ye, Hongmei Sun, Chen Zhang, Yu Dong, Zhenwei Shang, Hongchao Lv, Wenhua Lv, Mingming Zhang, Yongshuai JiangmedRxiv 2025 · DOI

Abstract

Multiple myeloma (MM) is an incurable clonal plasma cell malignancy that imposes a substantial global health burden. This study evaluates the global, regional, and national burden of MM by sex, age, and Socio-demographic Index (SDI) from 1990 to 2021, identifies causal risk factors, and projects temporal trends through 2050. Utilizing data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we employed Joinpoint regression for trend analysis, two-sample Mendelian randomization (MR) to establish causal relationships between weight-related factors and MM, and Bayesian age-period-cohort (BAPC) models for future projections. In 2021, the global age-standardized prevalence rate (ASPR) was 4.65 per 100,000 people. The burden was highest in high-SDI regions and among elderly populations. MR analysis confirmed high body mass index (BMI) and other obesity metrics as causal risk factors. While global incidence rates are predicted to decrease slightly by 2050, a concerning increase is projected within the 20–69 age group, necessitating targeted prevention strategies.

Introduction

Multiple myeloma (MM) is the second most common hematological malignancy worldwide. Characterized by the uncontrolled proliferation of plasma cells in the bone marrow, it leads to bone destruction, renal failure, and immune deficiency. Despite significant therapeutic advancements that have extended survival, MM remains largely incurable. As the global population ages and lifestyle-related risk factors—particularly obesity—become more prevalent, understanding the shifting epidemiological landscape of MM is critical for public health planning. This study provides a comprehensive analysis of MM burden over three decades and offers a data-driven forecast of the disease's trajectory over the next 30 years.

Methods

This research utilized a multi-faceted analytical framework based on the GBD 2021 dataset, which covers 204 countries and territories.

  1. Epidemiological Metrics: We analyzed prevalence, incidence, mortality, and disability-adjusted life years (DALYs).
  2. Trend Analysis: Joinpoint regression was used to calculate the Average Annual Percent Change (AAPC), identifying significant shifts in disease rates over time.
  3. Causal Inference: To move beyond simple correlation, we conducted a two-sample Mendelian randomization (MR) analysis using genetic variants from the OpenGWAS Project. This allowed us to assess the causal impact of BMI, waist circumference, and obesity on MM risk.
  4. Forecasting: Future incidence rates were projected through 2050 using the Bayesian age-period-cohort (BAPC) model, which accounts for historical trends in age and time periods.

Results

The global burden of MM has expanded dramatically. Between 1990 and 2021, the number of prevalent cases increased by 218.20%, reaching approximately 394,482 cases. In 2021, the age-standardized mortality rate (ASMR) was 1.40 per 100,000 people.

The distribution of MM is heavily influenced by socio-economic development. The highest age-standardized rates (ASRs) were consistently found in high-SDI regions, such as Australasia and North America. Specifically, Monaco and the Bahamas reported the highest age-standardized incidence, DALY, and mortality rates in 2021. Conversely, the lowest rates were observed in low-SDI regions, including parts of Oceania and Africa.

Demographic Disparities

Age and sex remain primary determinants of MM burden. Rates peaked in the elderly population (70+ years) and were significantly higher in males than in females across nearly all geographic regions. However, middle-SDI regions showed the most rapid upward trends in disease burden, suggesting that as these nations undergo economic transitions, their cancer profiles are increasingly resembling those of high-income countries.

Causal Risk Factors

One of the study's most significant findings is the causal link between metabolic health and MM. GBD 2021 data identified high BMI as a major risk factor, contributing to nearly 8% of global MM mortality. The MR analysis further solidified this, showing that BMI, waist circumference, hip circumference, and various classes of obesity are causal drivers of the disease. This relationship may be mediated by the production of interleukin-6 in adipose tissue, which promotes the growth of myeloma cells.

Projections to 2050

While the overall global age-standardized incidence rate is predicted to see a slight decline by 2050, the BAPC model reveals a troubling shift in age-specific demographics. The incidence of MM is projected to increase among individuals aged 20–69. This suggests that the disease may increasingly affect the working-age population, potentially due to the rising global prevalence of obesity and metabolic syndrome in younger cohorts.

Discussion and Conclusion

Multiple myeloma remains a significant and growing public health challenge. The massive increase in prevalence over the last 30 years reflects both an aging global population and improved diagnostic capabilities in high-SDI regions. However, the emerging burden in middle-SDI countries and the projected rise in younger age groups signal a need for a shift in prevention strategies.

The confirmation of obesity as a causal risk factor provides a clear target for intervention. Public health initiatives focused on weight management and metabolic health could significantly reduce the future incidence of MM. Furthermore, the disparity in burden between high and low SDI regions highlights the need for improved healthcare infrastructure and cancer registries in developing nations to ensure early diagnosis and equitable access to treatment.

In conclusion, while medical treatments for MM continue to evolve, the rising global burden—particularly among younger adults—demands a renewed focus on primary prevention and targeted screening for high-risk populations.

Summary updated

Abstract

Abstract IMPORTANCE MM was an incurable clonal plasma cell malignancy with substantial prevalence and incidence, which had resulted in a significant burden of disease. Our study aimed to evaluate the global, regional and national burden of MM by sex, age, and SDI from 1990 to 2021, along with associated risk factors and predicted temporal trends. OBJECTIVE To assess the global burden, epidemiological trends, and risk factors of MM and project its incidence rate by 2050. Design This is a systematic analysis of the global burden of MM from 1990 to 2021. Setting The study primarily analyzed the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) of MM from Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2021, by region, age, sex, and SDI. Participants The study builds on findings from the GBD 2021. Exposure Multiple myeloma. Main Outcomes and Measures The Joinpoint regression was used to describe the trends. Two-sample Mendelian randomization (MR) analysis was conducted to identify the causal relationship between weight-related risk factors and MM. The Bayesian age-period-cohort (BAPC) model was used to predict the future trend. Results In 2021, the age-standardized prevalence rate (ASPR) of MM was 4.65 (95% UI: 4.21 to 5.01) per 100,000 people, and the age-standardized mortality rate (ASMR) was 1.40 (95% UI: 1.24 to 1.52) per 100,000 people globally. The burden of MM was the highest in the high SDI region, with Monaco and Bahamas reporting the highest age-standardized incidence rate (ASIR), age-standardized DALY rate (ASDR), and ASMR in 2021. Simultaneously, ASRs peaked in the elderly population and were higher in males than in females. GBD 2021 reported high body mass index (BMI) as a risk factor for MM which was further confirmed by two-sample MR analysis. Additionally, BMI, waist circumference, obesity class 1, obesity class 2, overweight and hip circumference were also risk factors for MM. By 2050, the global incidence rate was predicted to decrease slightly but increase within the age group of 20-69. Conclusions and Relevance This study found that MM remained a significant public health issue, particularly in high SDI regions and among the elderly. A causal relationship exists between MM and body weight, indicating the need for targeted prevention and intervention strategies in high-risk regions and populations.
BibTeX
@misc{wang2025burden,
  author = {Chang Wang and Yan Guo and Ning Wang and Qianqian Ren and Xu Yuan and Songlin Lu and Yuping Zou and Ruilin Li and Jiacheng Wang and Linna Yuan and Wei She and Hongsheng Tian and Shuo Bi and Xuying Guo and Mao Ye and Hongmei Sun and Chen Zhang and Yu Dong and Zhenwei Shang and Hongchao Lv and Wenhua Lv and Mingming Zhang and Yongshuai Jiang},
  title = {{The burden trend and risk factors of multiple myeloma from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021}},
  year = {2025},
  doi = {10.1101/2025.04.20.25326120},
  howpublished = {medRxiv},
}
Figure